One hurdle down? FDA won ' t hold adcomm for BioMarin ' s hemophilia gene therapy after all

One hurdle down? FDA won't hold adcomm for BioMarin's hemophilia gene therapy after all The FDA may be taking its time reviewing BioMarin’s gene therapy for hemophilia A, but at least the biotech now has one fewer thing to worry about. While the agency has previously planned to convene an external…#genetherapy #readingendpoints #fda #endpoints #biomarin #hurdle #gene #therapy #roctavian #hemophilia
Source: Reuters: Health - Category: Consumer Health News Source Type: news